Search Results - "Tiseo, Marcello"

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer by Leonetti, Alessandro, Sharma, Sugandhi, Minari, Roberta, Perego, Paola, Giovannetti, Elisa, Tiseo, Marcello

“…Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-…”
Get full text

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC by Ramalingam, Suresh S, Vansteenkiste, Johan, Planchard, David, Cho, Byoung Chul, Gray, Jhanelle E, Ohe, Yuichiro, Zhou, Caicun, Reungwetwattana, Thanyanan, Cheng, Ying, Chewaskulyong, Busyamas, Shah, Riyaz, Cobo, Manuel, Lee, Ki Hyeong, Cheema, Parneet, Tiseo, Marcello, John, Thomas, Lin, Meng-Chih, Imamura, Fumio, Kurata, Takayasu, Todd, Alexander, Hodge, Rachel, Saggese, Matilde, Rukazenkov, Yuri, Soria, Jean-Charles

“…Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in EGFR . The median overall…”
Get full text

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance by Minari, Roberta, Bordi, Paola, Tiseo, Marcello

“…Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of…”
Get full text

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors by Leonetti, Alessandro, Facchinetti, Francesco, Zielli, Teresa, Brianti, Elena, Tiseo, Marcello

Get full text

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial by Camidge, D Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C H, Han, Ji-Youn, Hochmair, Maximilian J, Lee, Ki Hyeong, Delmonte, Angelo, García Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander, Gettinger, Scott N, Tiseo, Marcello, Lin, Huamao M, Gupta, Neeraj, Hanley, Michael J, Ni, Quanhong, Zhang, Pingkuan, Popat, Sanjay

“…Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related…”
Get full text

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer by Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James Chih-Hsin, Han, Ji-Youn, Lee, Jong-Seok, Hochmair, Maximilian J, Li, Jacky Yu-Chung, Chang, Gee-Chen, Lee, Ki Hyeong, Gridelli, Cesare, Delmonte, Angelo, Garcia Campelo, Rosario, Kim, Dong-Wan, Bearz, Alessandra, Griesinger, Frank, Morabito, Alessandro, Felip, Enriqueta, Califano, Raffaele, Ghosh, Sharmistha, Spira, Alexander, Gettinger, Scott N, Tiseo, Marcello, Gupta, Neeraj, Haney, Jeff, Kerstein, David, Popat, Sanjay

“…In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity…”
Get full text

Low PD-1 Expression in Cytotoxic CD8 + Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value by Mazzaschi, Giulia, Madeddu, Denise, Falco, Angela, Bocchialini, Giovanni, Goldoni, Matteo, Sogni, Francesco, Armani, Giovanna, Lagrasta, Costanza Annamaria, Lorusso, Bruno, Mangiaracina, Chiara, Vilella, Rocchina, Frati, Caterina, Alfieri, Roberta, Ampollini, Luca, Veneziani, Michele, Silini, Enrico Maria, Ardizzoni, Andrea, Urbanek, Konrad, Aversa, Franco, Quaini, Federico, Tiseo, Marcello

“…The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression are immune regulated. To determine whether distinct tissue…”
Get full text

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial by Camidge, D Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C H, Han, Ji-Youn, Hochmair, Maximilian J, Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander I, Gettinger, Scott N, Tiseo, Marcello, Lin, Huamao M, Liu, Yuyin, Vranceanu, Florin, Niu, Huifeng, Zhang, Pingkuan, Popat, Sanjay

“…In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced…”
Get more information

MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions by Leonetti, Alessandro, Assaraf, Yehuda G., Veltsista, Paraskevi D., El Hassouni, Btissame, Tiseo, Marcello, Giovannetti, Elisa

“…The introduction of EGFR-tyrosine kinase inhibitors (TKIs) has revolutionized the treatment and prognosis of non-small cell lung cancer (NSCLC) patients…”
Get full text

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC by Mazzaschi, Giulia, Facchinetti, Francesco, Missale, Gabriele, Canetti, Diana, Madeddu, Denise, Zecca, Alessandra, Veneziani, Michele, Gelsomino, Francesco, Goldoni, Matteo, Buti, Sebastiano, Bordi, Paola, Aversa, Franco, Ardizzoni, Andrea, Quaini, Federico, Tiseo, Marcello

“…•Immune checkpoint blockade (ICB) has shown unprecedented results in NSCLC.•Immune profiles predictive of ICB efficacy have not been entirely assessed.•Tissue…”
Get full text

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC by Bersanelli, Melissa, Minari, Roberta, Bordi, Paola, Gnetti, Letizia, Bozzetti, Cecilia, Squadrilli, Anna, Lagrasta, Costanza Anna Maria, Bottarelli, Lorena, Osipova, Ganna, Capelletto, Enrica, Mor, Marco, Tiseo, Marcello

Get more information

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome by Rossi, Giulio, Cavazza, Alberto, Spagnolo, Paolo, Sverzellati, Nicola, Longo, Lucia, Jukna, Agita, Montanari, Gloria, Carbonelli, Cristiano, Vincenzi, Giada, Bogina, Giuseppe, Franco, Renato, Tiseo, Marcello, Cottin, Vincent, Colby, Thomas V

“…The term diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) may be used to describe a clinico-pathological syndrome, as well as an…”
Get full text

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) by Gelsomino, Francesco, Tiseo, Marcello, Barbieri, Fausto, Riccardi, Ferdinando, Cavanna, Luigi, Frassoldati, Antonio, Delmonte, Angelo, Longo, Lucia, Dazzi, Claudio, Cinieri, Saverio, Colantonio, Ida, Sperandi, Francesca, Lamberti, Giuseppe, Brocchi, Stefano, Tofani, Lorenzo, Boni, Luca, Ardizzoni, Andrea

“…Background Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest…”
Get full text

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial by Huber, Rudolf M, Hansen, Karin H, Paz-Ares Rodríguez, Luis, West, Howard L, Reckamp, Karen L, Leighl, Natasha B, Tiseo, Marcello, Smit, Egbert F, Kim, Dong-Wan, Gettinger, Scott N, Hochmair, Maximilian J, Kim, Sang-We, Langer, Corey J, Ahn, Myung-Ju, Kim, Edward S, Kerstein, David, Groen, Harry J M, Camidge, D Ross

“…We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase-positive NSCLC. Patients were…”
Get more information

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients by Cortellini, Alessio, Chiari, Rita, Ricciuti, Biagio, Metro, Giulio, Perrone, Fabiana, Tiseo, Marcello, Bersanelli, Melissa, Bordi, Paola, Santini, Daniele, Giusti, Raffaele, Grassadonia, Antonino, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Malorgio, Francesco, Garufi, Carlo, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Iacono, Daniela, Migliorino, Maria Rita, Porzio, Giampiero, Cannita, Katia, Ficorella, Corrado, Buti, Sebastiano

“…Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in…”
Get full text

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer by Eltayeb, Kamal, La Monica, Silvia, Tiseo, Marcello, Alfieri, Roberta, Fumarola, Claudia

“…Lung cancer is the leading cause of cancer deaths worldwide. Most of lung cancer cases are classified as non-small cell lung cancers (NSCLC). EGFR has become…”
Get full text

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells by Bonelli, Mara A., Digiacomo, Graziana, Fumarola, Claudia, Alfieri, Roberta, Quaini, Federico, Falco, Angela, Madeddu, Denise, La Monica, Silvia, Cretella, Daniele, Ravelli, Andrea, Ulivi, Paola, Tebaldi, Michela, Calistri, Daniele, Delmonte, Angelo, Ampollini, Luca, Carbognani, Paolo, Tiseo, Marcello, Cavazzoni, Andrea, Petronini, Pier Giorgio

“…Malignant pleural mesothelioma (MPM) is a progressive malignancy associated to the exposure of asbestos fibers. The most frequently inactivated tumor…”
Get full text

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response by Del Re, Marzia, Bordi, Paola, Rofi, Eleonora, Restante, Giuliana, Valleggi, Simona, Minari, Roberta, Crucitta, Stefania, Arrigoni, Elena, Chella, Antonio, Morganti, Riccardo, Tiseo, Marcello, Petrini, Iacopo, Danesi, Romano

“…Background Circulating cell-free DNA (cfDNA) may help understand the molecular response to pharmacologic treatment and provide information on dynamics of…”
Get full text

K-RAS mutations indicating primary resistance to crizotinib in ALK -rearranged adenocarcinomas of the lung: Report of two cases and review of the literature by Mengoli, Maria Cecilia, Barbieri, Fausto, Bertolini, Federica, Tiseo, Marcello, Rossi, Giulio

“…Highlights • K-RAS and ALK alterations in NSCLC may co-exist. • K-RAS mutations confer crizotinib resistance to ALK-rearranged NSCLC. • K-RAS appears a strong…”
Get full text

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer by Landi, Lorenza, D’Incà, Federica, Gelibter, Alain, Chiari, Rita, Grossi, Francesco, Delmonte, Angelo, Passaro, Antonio, Signorelli, Diego, Gelsomino, Francesco, Galetta, Domenico, Giannarelli, Diana, Soto Parra, Hector, Minuti, Gabriele, Tiseo, Marcello, Migliorino, Maria Rita, Cognetti, Francesco, Toschi, Luca, Bidoli, Paolo, Piantedosi, Francovito, Calabro’, Luana, Cappuzzo, Federico

“…BackgroundBone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic…”
Get full text